Viking Therapeutics VKTX provided investors with an encouraging update during its third-quarter 2026 earnings call. During the Q&A session, CEO Brian Lian said the company was about 2.5 years away from a potential launch of its lead obesity candidate, VK2735. Based on this timeline, Viking could bring its obesity drug to market in the first half of 2029. This would mark a milestone for the clinical-stage company as it seeks to establish a presence in the obesity space. However, the bigger question is whether this timeline is achievable. Viking is currently advancing both the subcutaneous (SC) and oral formulations of VK2735 in separate phase III programs.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.